arformoterol	placebo	improvements in quality of life (overall St. George's Hospital Respiratory Questionnaire and Clinical COPD Questionnaire)	1748	1935	Significant improvements in quality of life (overall St. George's Hospital Respiratory Questionnaire and Clinical COPD Questionnaire) were observed with arformoterol vs placebo (P < .05).
arformoterol	placebo	incidence of AEs	19060	19165	Patients receiving arformoterol or placebo had a similar incidence of AEs (72.9% vs 68.2%, respectively).
arformoterol	placebo	Improvements in trough FEV1	1572	1746	Improvements in trough FEV1 and FVC were greater with arformoterol (least-squares mean change from baseline vs placebo: 0.051 L, P = .030 and 0.075 L, P = .018, respectively)
arformoterol	placebo	Improvements in trough FEV1	1572	1747	Improvements in trough FEV1 and FVC were greater with arformoterol (least-squares mean change from baseline vs placebo: 0.051 L, P = .030 and 0.075 L, P = .018, respectively).
arformoterol	placebo	Improvements in FVC	1572	1746	Improvements in trough FEV1 and FVC were greater with arformoterol (least-squares mean change from baseline vs placebo: 0.051 L, P = .030 and 0.075 L, P = .018, respectively)
arformoterol	placebo	Improvements in FVC	1572	1747	Improvements in trough FEV1 and FVC were greater with arformoterol (least-squares mean change from baseline vs placebo: 0.051 L, P = .030 and 0.075 L, P = .018, respectively).
arformoterol	placebo	first respiratory serious adverse event risk	1259	1363	Risk for first respiratory serious adverse event was 50% lower with arformoterol than placebo (P = .003)
arformoterol	placebo	first respiratory serious adverse event risk	1259	1364	Risk for first respiratory serious adverse event was 50% lower with arformoterol than placebo (P = .003).
